<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03946462</url>
  </required_header>
  <id_info>
    <org_study_id>H-44435</org_study_id>
    <nct_id>NCT03946462</nct_id>
  </id_info>
  <brief_title>Nitric Oxide During CPB to Reduce AKI in Neonates</brief_title>
  <official_title>A Prospective Randomized Controlled Trial of Supplemental Nitric Oxide During Cardiopulmonary Bypass to Reduce Acute Kidney Injury After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fabio Savorgnan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind, placebo-controlled pilot study to&#xD;
      investigate whether supplemental Nitric Oxide (NO) gas delivered during cardiac surgery with&#xD;
      cardiopulmonary bypass (CPB) reduces the incidence and impact of acute kidney injury (AKI) in&#xD;
      neonates undergoing surgery for congenital heart disease (CHD), when compared to placebo gas&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening: All patients undergoing either elective or emergency cardiac surgery will be&#xD;
      screened against the eligibility criteria.&#xD;
&#xD;
      Research Sample Collection: Blood and urine will be collected for the first 48 hours&#xD;
      admission and analyzed. The specific time points for these parameters will be: 2 hours, 6&#xD;
      hours, 12 hours 24 hours, and 48 hours post admission. Blood and urine parameters will also&#xD;
      be collected as a baseline pre-operative. Patient outcomes will be captured for 30 days post&#xD;
      operatively.&#xD;
&#xD;
      Research Data Collection: Baseline information will be collected. Other research related&#xD;
      variables collected during the surgical intervention and bypass. Additional information will&#xD;
      be collected 2 hours, 6 hours, 12 hours, 24 hours, and 48 hours after admission as well as&#xD;
      outcomes 30 days after the procedure.&#xD;
&#xD;
      Participants will be randomly allocated to the NO or control group in a 1:1 ratio.&#xD;
&#xD;
      This study is investigating a possible protective role for NO gas administration during&#xD;
      bypass on the subsequent development of AKI. NO is typically delivered via large, stand-alone&#xD;
      cylinders that are placed at the bedside (or adjacent to the patient) and is set up by&#xD;
      respiratory therapists. In this research study, the study gas (NO or placebo) will be&#xD;
      delivered directly into the bypass circuit at a constant gas flow. The placebo gas in this&#xD;
      study will be 21% (or atmospheric) oxygen, and will appear to all members of the clinical and&#xD;
      research teams (with the exception of the respiratory therapist responsible for setting it&#xD;
      up) indistinguishable from NO, rendering this a double-blind study for the patient (or&#xD;
      caregiver) and the investigators. This minimizes any possibility of bias in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>subjects, caregivers and research team members are blinded while respiratory therapists are unblinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>NGAL level</measure>
    <time_frame>48 hours</time_frame>
    <description>1 of 2 biomarkers to determine acute kidney injury (AKI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cystatin-C level</measure>
    <time_frame>48 hours</time_frame>
    <description>2 of 2 biomarkers to determine acute kidney injury (AKI)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>NO Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NO gas delivered during cardiac surgery</intervention_name>
    <description>intra-operative NO gas at 20ppm blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system.</description>
    <arm_group_label>NO Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo gas delivered during cardiac surgery</intervention_name>
    <description>placebo blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system. The placebo gas in this study will be 21% (or atmospheric) oxygen.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: &lt;/= 30 days&#xD;
&#xD;
          -  Gestational age: 38 weeks&#xD;
&#xD;
          -  Diagnosis: Congenital Heart Disease (CHD)&#xD;
&#xD;
          -  Planned surgery to include cardiopulmonary bypass (CPB )for underlying CHD&#xD;
&#xD;
          -  Consent of parent/guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently receiving or has received inhaled nitric oxide (NO) or other nitrogen donors&#xD;
             such as sildenafil or nitroprusside&#xD;
&#xD;
          -  Pre-existing acute kidney injury (AKI) as per the AKIN criteria;&#xD;
&#xD;
          -  Cardiac arrest within one week prior consent;&#xD;
&#xD;
          -  Prior cardiac surgery with CPB procedure;&#xD;
&#xD;
          -  Prior history of Extra Corporeal Membrane Oxygenation (ECMO)&#xD;
&#xD;
          -  Use of another investigational drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Savorgnan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Children's Hospital / Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabio Savorgnan, MD</last_name>
    <phone>832-826-6230</phone>
    <email>fabio.savorgnan@bcm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabio Savorgnan, MD</last_name>
    </contact>
    <contact_backup>
      <phone>832-826-6230</phone>
      <email>fabio.savorgnan@bcm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Fabio Savorgnan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lara Shekerdemian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Checchia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Fabio Savorgnan</investigator_full_name>
    <investigator_title>Principal Investigator / Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Congenital Heart Disease</keyword>
  <keyword>CHD</keyword>
  <keyword>Acute Kidney Injury</keyword>
  <keyword>AKI</keyword>
  <keyword>Cardiopulmonary bypass</keyword>
  <keyword>CPB</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>neonate</keyword>
  <keyword>infant</keyword>
  <keyword>nitric oxide</keyword>
  <keyword>NO</keyword>
  <keyword>gestational age</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

